exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087601 RNA Name: hsa-miR-103a-3p RNA Type: miRNA Chromosome: chr5 Starnd: - Coordinate: Start Site(bp): 168560904 End Site(bp): 168560926 External Links: hsa-miR-103a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RCCD1 chr15 90954870 90963125 + CA12 chr15 63321378 63381846 - AMER1 chrX 64185117 64205708 - PLPP6 chr9 4662294 4665258 + ERG28 chr14 75649791 75660876 - SCAMP4 chr19 1905372 1926013 + DPP3 chr11 66480013 66509657 + AC011455.2 chr19 38915404 38949855 - UBN1 chr16 4846665 4882401 + TMX2 chr11 57712593 57740973 + RNF157 chr17 76142465 76240493 - NAA60 chr16 3443649 3486953 + MRPS2 chr9 135499984 135504673 + TSPYL2 chrX 53082367 53088540 + KLHL21 chr1 6590724 6614607 - TUBA1B chr12 49127782 49131397 - STEAP3 chr2 119223831 119265652 + MRPL3 chr3 131462212 131502983 - STK16 chr2 219245455 219250337 + ABCF2 chr7 151207837 151227166 - RPS6KA3 chrX 20149911 20267519 - DCAF7 chr17 63550477 63594279 + CNN2 chr19 1026586 1039068 + SRPK1 chr6 35832966 35921342 - ZNF697 chr1 119619377 119648266 - LYSMD2 chr15 51723011 51751585 - PODXL chr7 131500262 131558217 - EBP chrX 48521799 48528716 + RPS14 chr5 150442635 150449739 - PKM chr15 72199029 72231822 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0000652 chr15 90984737 90986710 + hsa_circ_0001472 chr5 36953719 36976504 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC003092.1 chr7 94022833 94066661 + AC018521.1 chr17 47945424 47981736 + AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC093297.2 chr5 44826076 44828592 + AL137127.1 chr1 19072110 19075511 - FGD5-AS1 chr3 14920347 14948424 - H19 chr11 1995176 2001470 - LINC00294 chr11 33076149 33079454 + LINC00662 chr19 27681072 27794005 - LINC02035 chr3 122886941 122892416 + MIR503HG chrX 134543119 134546642 - NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - NUTM2B-AS1 chr10 79661394 79826594 - STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + TMEM147-AS1 chr19 35540738 35546029 - TTC28-AS1 chr22 27919376 28008581 + TTN-AS1 chr2 178521183 178779963 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.